source
- GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA reviewGSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
- Ending federally funded animal testing could stall xenotransplantation breakthroughsTransplant surgeon Joshua Mezrich argues that recent moves to end federally funded animal testing could impede the development of xenotransplantation, a field that aims to use pig organs for human…